Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

SUPRASELECTIVE INJECTION OF INTRAARTERIAL MELPHALAN AS THE PRIMARY TREATMENT FOR LATE PRESENTATION UNILATERAL MULTIFOCAL STAGE VB RETINOBLASTOMA

AZIZ, HASSAN A. MD*; BOUTRID, HINDA MS*; MURRAY, TIMOTHY G. MD*; BERROCAL, AUDINA MD*; WOLFE, STACEY QUINTERO MD; PINA, YOLANDA BS*; DORFMAN, MARK MD*; MOFTAKHAR, ROHAM MD; FERNANDES, CRISTINA E. MD; REICHBACH, JENNIFER NP-C; AZIZ-SULTAN, MOHAMMAD ALI MD

doi: 10.1097/IAE.0b013e3181cbda0f
Articles
Buy

Purpose: The purpose of this study was to report a case of a 7-year-old girl with unilateral, multifocal Reese Ellsworth Stage Vb retinoblastoma who was successfully treated using intraarterial chemotherapy infusion as the primary therapy.

Methods: This is an interventional case report. A 7-year-old girl presented with advanced unilateral retinoblastoma. The patient received intraarterial melphalan infusion therapy as the primary treatment.

Results: Complete tumor resolution was seen at 1 month after intraarterial melphalan infusion.

Conclusion: This case of advanced retinoblastoma in a 7-year-old girl was successfully treated with intraarterial melphalan infusion alone. Treatment resulted in complete resolution of the tumor 1 month after treatment. In comparison with systemic chemotherapy, intraarterial melphalan infusion therapy may be a less toxic and more effective primary treatment option in the future management of advanced retinoblastoma.

A 7-year-old girl presented with unilateral, multifocal advanced retinoblastoma and was administered intraarterial melphalan infusion as primary treatment. The tumor showed complete resolution 1 month after treatment without need for systemic chemotherapy, enucleation, or radiation. The clinical course and treatment of tumors were documented with fundus photography and echography.

From the *Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida; †Department of Neuro-radiology/Neurosurgery, Jackson Memorial Hospital, Miami, Florida; ‡Department of Pediatric Hematology/Oncology, Jackson Memorial Hospital, Miami, Florida.

The authors have no proprietary interest or potential conflicts of interest in the subject matter or topics discussed in this article.

Reprint requests: Timothy G. Murray, MD, MBA, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136; e-mail: tmurray@med.miami.edu

© The Ophthalmic Communications Society, Inc.